Recruiting

PhageTech Virus BioResistor

Sponsor:

PhageTech, Inc.

Code:

NCT04756284

Conditions

Bladder Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.

Conditions

Bladder Cancer

Study ID

NCT04756284

Start date

Feb 8, 2021

Status verified date

Feb, 2021

Completion date

Nov 11, 2021

Anticipated

Primary completion date

Nov 11, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Male and female patients ≥ 18 years
2. Previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy
3. Patients with suspected bladder tumor undergoing surveillance cystoscopy
4. Patients must provide written Informed Consent.

Exclusion Criteria:

1. Patients unable or unwilling to sign the informed consent
2. Age < 18 years
3. Known HIV/HCV/HBV (information from clinical history).

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Arms

Bladder Tumor Positive

Patients with previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy or suspected bladder tumor undergoing surveillance cystoscopy.

Bladder Tumor Negative

Patients with no suspected bladder tumor.

Primary outcome measure

  • Successful identification of bladder tumor biomarkersBiomarkers in Patients Under Active BCa Surveillance [ Time Frame: Up to 1 year ]

Central Contacts and Locations

Central contacts

Rodney Brenneman

949-433-6007rbrenneman@phagetech.com

Locations

Providence Saint John's Health Center and the Saint John's Cancer Institute

Recruiting

Santa Monica, California, United States, 90404

Contacts

Lisa van Kreuningen, M.S.

310-582-7053lisa.vankreuningen@providence.org

More Information

Sponsor

PhageTech, Inc.

Last update posted

Feb 16, 2021

Last verified

Feb, 2021

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by PhageTech, Inc. on 2021-02-16.